---
id: "question-publisher-ai-licensing"
type: "open-question"
source_timestamps: ["§ The 4C Framework for Building Generative Readiness"]
tags: ["legal", "publishing", "copyright"]
related: ["contrarian-paywalls-hurt-influence", "question-ai-liability-governance"]
resolutionPath: "Observation of upcoming legal settlements and licensing agreements between major LLM providers (OpenAI, Anthropic) and academic publishing conglomerates."
sources: ["geo"]
sourceVaultSlug: "hbr-seg-geo"
originDay: 3
articleStem: "hbr-tier1-01-gen-ai-b2b-buying"
sourceUrl: "https://hbr.org/2026/06/how-gen-ai-is-disrupting-b2b-buying-decisions"
sourceTitle: "How Gen AI is Disrupting B2B Buying Decisions"
---
# How will copyright licensing evolve between medical publishers and AI companies?

**Open question:** As AI bypasses traditional publisher platforms (top-tier medical journals), there is growing concern over content utilization and revenue models. It remains unresolved how linkages through **Model Context Protocols (MCPs)** and copyright licensing will be structured to balance open LLM access with publisher monetization.

**Why it's open:** It is the direct commercial tension behind [[contrarian-paywalls-hurt-influence]] — if paywalled prestige content is invisible to open LLMs, publishers must either open up or license.

**Resolution path:** Watch upcoming legal settlements and licensing agreements between major LLM providers (OpenAI, Anthropic) and academic publishing conglomerates. **Enrichment note:** emerging deals (e.g. LLM providers with Elsevier/Springer Nature) are already licensing paywalled content for training and retrieval, suggesting the 'dual-track' strategy in [[contrarian-paywalls-hurt-influence]] will become standard.